Background and Purpose: It is unestablished whether andexanet alfa, compared with
guideline-based usual care including prothrombin complex concentrates, is associated with …

Background Patients with acute intracerebral hemorrhage who are receiving factor Xa
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …

Objective Intracranial hemorrhage is a life threatening complication of factor Xa inhibitors.
Except for results of the open-label, single-arm ANNEXA-4 study, published real-world …

Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa)
developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of …

Abstract Background/Objective There are limited data on the risks and benefits of using
andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F …

Abstract Background/Objective Intracranial bleeding (ICB) is a feared complication of
systemic anticoagulation. Factor Xa inhibitors (FXaI) are used frequently due to their …

Objective To investigate parameters associated with hematoma enlargement in non–vitamin
K antagonist oral anticoagulant (NOAC)‐related intracerebral hemorrhage (ICH). Methods …

Background There is limited information directly comparing andexanet alfa (AA) versus four-
factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage (ICH) on …

Importance Although the use of factor Xa (FXa) inhibitors has increased substantially over
the past decade, there are limited data on characteristics and outcomes of FXa inhibitor …

Background Well-designed studies with sufficient sample size comparing andexanetáalfa vs
4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate …